Peptide Knowledge Base · Longevity

Vilon: what it is, what the evidence says, and its real status

Another Khavinson 'bioregulator,' this one pitched for immune and aging support.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does Vilon work?

A dipeptide proposed by the Khavinson school as an immune/longevity 'bioregulator' of gene expression.

What it does — and what it does not do

What it does: Claimed in Russian-origin work to support immune function and aging.

What it does not do: It is not independently validated.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

Russian-origin claims; minimal independent replication

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Independent replication is minimal; outcomes unconfirmed.

WADA status: Not prohibited.

How it is taken

No established human clinical dosing; research-stage.

Who should not take it

Not characterized in independent practice; no established safety profile.

Sources

Khavinson peptide-bioregulator literature (limited independent replication)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.